AusperBio Raises $120 Million To Push a Hepatitis B Functional Cure
Chronic hepatitis B affects over 250 million people in the world. What’s available as the solution today can only manage the virus, it can rarely cure it. So, most patients The post AusperBio Raises $120 Million To Push a Hepatitis B Functional Cure appeared first on Ventureburn .
AusperBio Therapeutics has raised $120 million in a Series C funding round to advance its lead drug candidate AHB-137 in a search for a hepatitis B functional cure. Chronic hepatitis B infects over 250 million people worldwide, but existing treatments only manage the virus and cannot cure it. AusperBio aims to develop RNA-based therapies that can control the virus enough for patients to stop treatment altogether.
The funding will be used to run Phase 3 trials for AHB-137, prepare for commercialization, and expand its pipeline with additional RNA drugs like AHB-171.
Written by urgent.news from Ventureburn's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
